{"id":59954,"date":"2025-01-13T07:18:02","date_gmt":"2025-01-13T07:18:02","guid":{"rendered":"https:\/?p=59954"},"modified":"2025-01-13T07:18:02","modified_gmt":"2025-01-13T07:18:02","slug":"top-3-stocks-to-watch-this-week","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/","title":{"rendered":"Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV"},"content":{"rendered":"<p>This week, Stock Target Advisor highlights three promising stocks: PACS Group (NYSE: PACS), Oruka Therapeutics (NASDAQ: ORKA), and Constellium NV (NYSE: CSTM). Backed by AI analysis and expert insights, these companies offer compelling opportunities for growth-focused investors. Let\u2019s dive into what makes these stocks stand out.<\/p>\n<h2>1. PACS Group <a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/PACS\">(NYSE: PACS)<\/a><\/h2>\n<p>PACS Group has been gaining momentum in the skilled nursing facilities sector. Currently trading at <strong>$12.83<\/strong>, PACS is estimated to have an AI-backed target price of <strong>$38<\/strong>, offering a <strong>200% upside<\/strong>.<\/p>\n<h3>Key Highlights:<\/h3>\n<ul>\n<li><strong>Aggressive Expansion:<\/strong> Recent acquisitions in Tennessee have added 1,300+ beds, expanding PACS\u2019s reach across 17 states.<\/li>\n<li><strong>Sector Trends:<\/strong> The shift towards value-based care and Medicare Advantage, enrolling over 35.7 million individuals in 2025, aligns with PACS\u2019s strategy.<\/li>\n<li><strong>Strong Fundamentals:<\/strong> With a <strong>94% occupancy rate<\/strong>, PACS showcases efficient operations and high-quality service delivery.<\/li>\n<\/ul>\n<h3>Risks to Consider:<\/h3>\n<p>Legal challenges over delayed financial reporting might impact short-term investor sentiment, but PACS&#8217;s robust growth strategy makes it a solid long-term pick.<\/p>\n<p><iframe title=\"Top 3 Stock Picks of the Week of January 13, 2025 | AI-Powered Insights from Stock Target Advisor\" width=\"840\" height=\"473\" src=\"https:\/\/www.youtube.com\/embed\/jD4Mw6aZfdE?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p>Discover this week\u2019s top AI-backed stock picks with insights on their growth potential and market strategies. Watch the full analysis <a href=\"https:\/\/youtu.be\/jD4Mw6aZfdE?si=Ev09AGWXK2v2ZS_V\">here!<\/a><\/p>\n<h2>2. Oruka Therapeutics <a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NSD\/ORKA\">(NASDAQ: ORKA)<\/a><\/h2>\n<p>Oruka Therapeutics focuses on biotechnology innovations for chronic skin conditions like psoriasis. Trading at <strong>$15.72<\/strong>, Oruka\u2019s AI-backed target price is <strong>$42.63<\/strong>, presenting a potential <strong>172% upside<\/strong>.<\/p>\n<h3>Key Highlights:<\/h3>\n<ul>\n<li><strong>Cutting-Edge R&amp;D:<\/strong> Phase I trials for ORKA-001, a long-lasting antibody for psoriasis, signal transformative possibilities in chronic disease management.<\/li>\n<li><strong>Financial Strength:<\/strong> With over <strong>$400 million<\/strong> in cash reserves, Oruka has the resources to advance its pipeline.<\/li>\n<li><strong>Growing Visibility:<\/strong> Inclusion in the Nasdaq Biotechnology Index increases investor confidence and market interest.<\/li>\n<\/ul>\n<h3>Risks to Consider:<\/h3>\n<p>While Oruka is relatively new, its innovative focus and strong cash position mitigate concerns about its long-term viability.<\/p>\n<p>Is now the time to buy ORKA:NSD? Access our <a href=\"https:\/\/www.stocktargetadvisor.com\/detail_page_report\/Report?symbolstring=ORKA&amp;symbolstringinput=ORKA,QQQ&amp;endDate=2025-01-12&amp;startDate=2024-01-12&amp;hige=1&amp;score=100\">full analysis report here<\/a>, it\u2019s free.<\/p>\n<h2>3. Constellium NV <a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/CSTM\">(NYSE: CSTM)<\/a><\/h2>\n<p>Constellium NV, trading at <strong>$10.35<\/strong>, has a 12-month AI-backed target price of <strong>$23.60<\/strong>, offering a <strong>128% upside<\/strong>. As a leader in lightweight aluminum products, it serves industries like aerospace, automotive, and packaging.<\/p>\n<h3>Key Highlights:<\/h3>\n<ul>\n<li><strong>Sustainability Focus:<\/strong> Recently recognized with Stellantis\u2019 Supplier of the Year award for Corporate Social Responsibility.<\/li>\n<li><strong>Market Demand:<\/strong> Aluminum demand is projected to rise <strong>40% by 2030<\/strong>, driven by electric vehicle adoption and automotive lightweighting.<\/li>\n<li><strong>Strong Financials:<\/strong> Constellium\u2019s management excels in capital utilization, equity returns, and free cash flow generation.<\/li>\n<\/ul>\n<h3>Risks to Consider:<\/h3>\n<p>Challenges like high debt levels and supply chain disruptions could impact short-term performance. However, Constellium&#8217;s alignment with global sustainability trends positions it for long-term growth.<\/p>\n<p>Ready to take your investments to the next level? For a limited time, get 70% off on Stock Target Advisor. Get started <a href=\"https:\/\/www.stocktargetadvisor.com\/pricing?utm_source=top_bar&amp;utm_medium=web&amp;utm_campaign=new%20year\">here!<\/a><\/p>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/pricing?utm_source=top_bar&amp;utm_medium=web&amp;utm_campaign=new%20year\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-54040 size-full\" src=\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2024\/09\/STA-Email-Banner.jpg\" alt=\"Offer\" width=\"701\" height=\"192\" srcset=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/09\/STA-Email-Banner.jpg 701w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/09\/STA-Email-Banner-300x82.jpg 300w, https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2024\/09\/STA-Email-Banner-150x41.jpg 150w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 984px) 61vw, (max-width: 1362px) 45vw, 600px\" \/><\/a><\/p>\n<h3>Conclusion:<\/h3>\n<p>PACS Group, Oruka Therapeutics, and Constellium NV are three stocks to watch this week. With AI-driven analysis highlighting their growth potential, they cater to investors seeking substantial returns in dynamic sectors.<\/p>\n<p>Want to learn more? Explore deeper insights at <a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor<\/a> and share your thoughts on these <a href=\"https:\/\/www.stocktargetadvisor.com\/top-stocks\">top picks<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This week, Stock Target Advisor highlights three promising stocks: PACS Group (NYSE: PACS), Oruka Therapeutics (NASDAQ: ORKA), and Constellium NV (NYSE: CSTM). Backed by AI&#8230;<\/p>\n","protected":false},"author":17,"featured_media":59956,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-59954","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV<\/title>\n<meta name=\"description\" content=\"Dive into Stock Target Advisor\u2019s weekly highlights featuring PACS Group, Oruka Therapeutics, and Constellium NV as top investment choices.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV\" \/>\n<meta property=\"og:description\" content=\"Dive into Stock Target Advisor\u2019s weekly highlights featuring PACS Group, Oruka Therapeutics, and Constellium NV as top investment choices.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-13T07:18:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/01\/STAs-Blog-Images-2025-01-13T121708.214.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1256\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV\",\"datePublished\":\"2025-01-13T07:18:02+00:00\",\"dateModified\":\"2025-01-13T07:18:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/\"},\"wordCount\":503,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/\",\"name\":\"Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2025-01-13T07:18:02+00:00\",\"dateModified\":\"2025-01-13T07:18:02+00:00\",\"description\":\"Dive into Stock Target Advisor\u2019s weekly highlights featuring PACS Group, Oruka Therapeutics, and Constellium NV as top investment choices.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV","description":"Dive into Stock Target Advisor\u2019s weekly highlights featuring PACS Group, Oruka Therapeutics, and Constellium NV as top investment choices.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/","og_locale":"en_US","og_type":"article","og_title":"Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV","og_description":"Dive into Stock Target Advisor\u2019s weekly highlights featuring PACS Group, Oruka Therapeutics, and Constellium NV as top investment choices.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2025-01-13T07:18:02+00:00","og_image":[{"width":2400,"height":1256,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2025\/01\/STAs-Blog-Images-2025-01-13T121708.214.png","type":"image\/png"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV","datePublished":"2025-01-13T07:18:02+00:00","dateModified":"2025-01-13T07:18:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/"},"wordCount":503,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/","name":"Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2025-01-13T07:18:02+00:00","dateModified":"2025-01-13T07:18:02+00:00","description":"Dive into Stock Target Advisor\u2019s weekly highlights featuring PACS Group, Oruka Therapeutics, and Constellium NV as top investment choices.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/top-3-stocks-to-watch-this-week\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Top 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NV"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/59954","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=59954"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/59954\/revisions"}],"predecessor-version":[{"id":59957,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/59954\/revisions\/59957"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/59956"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=59954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=59954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=59954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}